BioCryst Pharmaceuticals (BCRX) Shares Gap Up to $4.91

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped up before the market opened on Wednesday . The stock had previously closed at $4.63, but opened at $4.91. BioCryst Pharmaceuticals shares last traded at $5.44, with a volume of 2501800 shares.

BCRX has been the subject of a number of recent research reports. Royal Bank of Canada initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 8th. Finally, Barclays initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $8.63.

The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. The stock has a market capitalization of $572.72, a P/E ratio of -9.00 and a beta of 3.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The business had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. BioCryst Pharmaceuticals’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 64,310 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $23,762,000. Alyeska Investment Group L.P. bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $2,358,000. Allianz Asset Management GmbH increased its position in shares of BioCryst Pharmaceuticals by 35.5% during the third quarter. Allianz Asset Management GmbH now owns 159,364 shares of the biotechnology company’s stock worth $835,000 after acquiring an additional 41,727 shares in the last quarter. VHCP Management II LLC increased its position in shares of BioCryst Pharmaceuticals by 27.9% during the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock worth $16,587,000 after acquiring an additional 690,290 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 4.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock worth $1,678,000 after acquiring an additional 12,267 shares in the last quarter. 84.69% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3126649/biocryst-pharmaceuticals-bcrx-shares-gap-up-to-4-91.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.